Stemline Therapeutics Presents SL-401 Lead-in Results from

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH

NEW YORK, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ) announced today the presentation of SL-401 lead-in data from its ongoing Phase 2 trial in acute myeloid leukemia (AML) in remission with minimal residual disease (MRD) and ongoing Phase 2 trial in high-risk myeloproliferative neoplasms (MPN) at the 2016 American Society of Hematology (ASH) Annual Meeting. The AML/MRD results were delivered via oral presentation by Andrew A. Lane, M.D., Ph.D., from the Dana-Farber Cancer Institute (Boston, MA) and the MPN results were presented by Mrinal S. Patnaik, M.D. from the Mayo Clinic (Rochester, MN).

The full presentations are available on the Stemline website, under the “Scientific Presentations” tab (see: http://www.stemline.com/scientific-presentations.asp ).

Safety Overview

  • SL-401 was found to be safe and well tolerated, and side effects were predictable and manageable. The lead-in dose escalation stages of both Phase 2 studies (3 x 3 design) were completed without dose limiting toxicity (DLT) and a maximum tolerated dose (MTD) was not reached in either study (n=9 patients in AML/MRD lead-in; n=9 patients in MPN lead-in). 12 ug/kg/day was the highest tested dose in both studies and is currently the dose level being used in the expansion stage of both studies.

Efficacy Overview

  • AML/MRD - Early signs of efficacy in the AML study included an MRD+ AML patient who sustained a decrease in MRD, determined locally, treated at 12 ug/kg/day who then went on to stem cell transplant. The expansion stage is currently enrolling and, for uniformity, will utilize a central facility for MRD analysis.
  • MPN - Early signs of efficacy in the MPN study including a patient with chronic myelomonocytic leukemia (CMML) who sustained a bone marrow complete response (BMCR) and reduction in spleen size. The expansion stage is currently enrolling CMML as well as additional MPN types including myelofibrosis, mastocytosis, and primary eosinophilic disorder.

Andrew A. Lane, M.D., Ph.D., lead author on the AML study, commented, “Given the unacceptably high relapse rates seen in AML, MRD has emerged as an important predictor of relapse with CD123 as a key target for therapy. The preliminary results seen with SL-401 in this setting are promising. We look forward to enrolling patients in the expansion stage of the trial as we continue to optimize and refine methods to assess and follow MRD.”

Mrinal S. Patnaik, M.D., lead author on the MPN study, noted, “The early data from the dose escalation portion of the trial suggests SL-401 can be dosed safely in this patient population. Additionally, we are observing encouraging signs of clinical activity in several patients. We look forward to enrolling patients in the expansion stage of the trial.”

About Stemline Therapeutics Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range of malignancies. SL-401 is being advanced through a potentially pivotal Phase 2 trial in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an indication for which SL-401 has been granted Breakthrough Therapy Designation (BTD) by the FDA. SL-401 has demonstrated high overall response rates (ORR), with multiple complete responses (CRs), in both first-line and relapsed/refractory patients, and treatment duration and frequency of bridge to transplant have been trending favorably. SL-401 is also being advanced through Phase 1/2 trials of patients with additional malignancies including acute myeloid leukemia (AML) in remission with minimal residual disease (MRD), high-risk myeloproliferative neoplasms (MPN), and relapsed/refractory multiple myeloma (in combination with pomalidomide). SL-801 is a novel oral small molecule reversible inhibitor of XPO1 that has demonstrated broad in vivo and in vitro preclinical activity in a wide array of solid and hematologic malignancies. A Phase 1 trial with SL-801 is open and enrolling patients with advanced solid tumors, and a Phase 1 trial in hematologic malignancies is planned. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. A Phase 2 trial with SL-701 in adult patients with second-line glioblastoma multiforme (GBM) is ongoing. For more information about Stemline Therapeutics, please visit www.stemline.com .

Forward-Looking Statements Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact Investor Relations Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email: investorrelations@stemline.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 49

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 205

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 113

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 68

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 89

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 130

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 19

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 142

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 148

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading
TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Innovations in Cannabinoid Medicine at Avicanna's Symposium

Updated Category News Views 131

Avicanna's 5th Medical Symposium on Cannabinoid Medicine On June 6, a well-anticipated medical symposium will be hosted by Avicanna Inc., a prominent biopharmaceutical company dedicated to the innovative exploration of cannabinoid-based medicine. This exciting event, taking place at the MaRS Discovery District, aims to bring together healthcare practitioners and...

Continue Reading
Gordian's Exciting New Initiative for Public Facility Planning

Updated Category News Views 277

Gordian's New Sourcewell Contract Gordian, a well-known provider of data-driven solutions for various phases of the building lifecycle, has recently secured a significant contract with Sourcewell. This partnership will broaden Gordian’s offerings to numerous government and educational organizations eager to enhance their facility planning capabilities. Facilitating...

Continue Reading
Paramount Global CFO Transition: A New Era Begins

Updated Category News Views 251

Paramount Global Announces Significant Leadership Change Paramount Global (NASDAQ: PARA) has made a noteworthy announcement regarding its executive leadership. Naveen Chopra, who has been serving as the Chief Financial Officer and Executive Vice President, will be departing from the company to explore new opportunities. The company's Board of Directors has stated that...

Continue Reading
Explore the Potential of Axsome, CRISPR, and Pfizer Stocks

Updated Category News Views 134

Back in 2023, the stock market was a mixed bag, with plenty of sectors showing serious signs of overvaluation. You had legends like Warren Buffett sitting on a mountain of cash, clearly indicating he saw overpriced stocks everywhere. When seasoned investors hit the brakes on buying due to high valuations, it’s like an alarm bell for everyone else—caution was in the...

Continue Reading
Boeing's Production Delays and Its Impact on Suppliers

Updated Category News Views 245

A Closer Look at Boeing's Production Setbacks Boeing Co has recently notified its suppliers about a significant change to a key production milestone for its 737 MAX aircraft. This adjustment, which extends the timeline by six months, has raised concerns within the aviation industry. Sources indicate that the new objective is to achieve an output of 42 jets per month by...

Continue Reading